AZN241018C77000
- 1.35
- 0.000.00%
AstraZeneca Newsroom
Hutchmed, AstraZeneca's Lung Cancer Combo Shrinks Tumors in Mid-stage Study
AstraZeneca Hits 4-week High
GSK Says Depemokimab For Chronic Rhinosinusitis Reduces Nasal Polyp Size, Nasal Obstruction Versus Placebo At One Year
AstraZeneca's Lung Cancer Drug Enhertu Gets Conditional Approval in China
Daiichi Sankyo/astrazeneca (AZN.US)'s 'Tecentriq' has been approved in China.
On October 14, the official website of the China National Medical Products Administration (NMPA) reported that the new indication for lung cancer of the injection monoclonal antibody trastuzumab deruxtecan (Enhertu) applied by Daiichi Sankyo has been approved for marketing. Trastuzumab deruxtecan is a HER2-targeted antibody-drug conjugate developed jointly by Astrazeneca (AZN.US) and Daiichi Sankyo.
AstraZeneca Expanding R&D Pipeline in China
GSK Settles Majority Of Zantac Lawsuits, But Pipeline Doubts Remain
Express News | AstraZeneca PLC Reports 9.9% Passive Stake in Conduit Pharmaceuticals Inc as of August 7 - SEC Filing
Astrazeneca (AZN.US) has obtained approval for listing its new antibody drug with new indications in China.
Astrazeneca (AZN.US) new antibody drug new indication has been accepted for listing application in China.
AstraZeneca Cut to Hold From Buy by Intron Health
AstraZeneca Target Cut to GBP120 From GBP140 by Intron Health
BenevolentAI to Present on Explainable AI for Drug Discovery at BioTechX Europe 2024
Alexion, AstraZeneca Rare Disease Data at the 2024 AANEM Annual Meeting and MGFA Scientific Session Further Demonstrate Advancement in GMG Care
cspc pharma's early trading rose by more than 6%, the group signed an exclusive licensing agreement with astrazeneca.
CSPC Pharma (01093) rose 5.51% in the morning session, now at 7.09 Hong Kong dollars, with a turnover of 0.585 billion Hong Kong dollars. CSPC Pharma has issued an announcement.
HK stocks unusual movement | cspc pharma (01093) surged more than 6% in the morning, entering into an exclusive authorization agreement with astrazeneca, with a total consideration of 2 billion US dollars.
CSPC Pharma(01093) surged over 6% in early trading, as of press time, up 3.87% to 6.98 Hong Kong dollars, with a turnover of 0.497 billion Hong Kong dollars.
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
Astrazeneca (AZN) Loses -5.29% in 4 Weeks, Here's Why a Trend Reversal May Be Around the Corner
Goldman Sachs: Buy rating on cspc pharma, the trade with astrazeneca is an important step in global expansion.
Oct 9, Goldman Sachs released a research report, giving CSPC Pharma a target price of 10.03 Hong Kong dollars based on the sum-of-the-parts valuation method (SOTP), reflecting a 40.9% upside potential, and rated it as a "buy". The report stated that CSPC Pharma announced plans to license YS2302018 (a small molecule inhibitor of lipoprotein(a) [Lp(a)] in preclinical stage) and any products containing YS2302018 globally. This marks the company's first collaboration with astrazeneca, which the bank considers an important step in the company's global expansion. The company aims to complete 1-2 more global deals by 2024.
Goldman Sachs: Initiates a "buy" rating on cspc pharma with a target price of 10.03 Hong Kong dollars.
Goldman Sachs released a research report stating a 'buy' rating for cspc pharma (01093) with a target price of 10.03 Hong Kong dollars. The company aims to complete 1-2 BD trades within 2024, emphasizing the continuous review of product lines and strengthening business expansion efforts. The bank expects more trades to occur in the future. It was noted that cspc pharma announced plans to authorize YS2302018 (a small molecule inhibitor of lipoprotein(a) (Lpa) in the preclinical stage) and any products containing YS2302018 globally. The company's first collaboration with Astrazeneca, according to the bank, is the company's global expansion.
Arcus a New Overweight at Wells Fargo on Potential of Casdatifan in Kidney Cancer